Overcoming inefficiencies in the development of personalized medicine
| Autor: | H. Sebastian Heese, Daniel Lütkemeyer, David A. Wuttke |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
050210 logistics & transportation
021103 operations research Information Systems and Management General Computer Science Revenue sharing business.industry 05 social sciences 0211 other engineering and technologies 02 engineering and technology Management Science and Operations Research Business model Industrial and Manufacturing Engineering Modeling and Simulation 0502 economics and business New product development Cost sharing Product (category theory) Personalized medicine business Industrial organization Pharmaceutical industry Companion diagnostic |
| Zdroj: | European Journal of Operational Research. 290:278-296 |
| ISSN: | 0377-2217 |
| DOI: | 10.1016/j.ejor.2020.08.013 |
| Popis: | The pharmaceutical industry faces a radical change in its business model. Whereas one-size-fits-all blockbuster drugs dominated in the past, today technological breakthroughs like the decoding of the human genome allow pharmaceutical firms to develop more customized products. This so-called personalized medicine can only work if a product tandem of specialized drug and companion diagnostic test exists, making new product development processes interdependent. We consider a pharmaceutical firm and a diagnostic firm that develop such a product tandem for personalized medicine. We show that the dependence on each other and the diagnostic firm’s option to postpone R&D activities lead to systematic inefficiencies in the development of personalized medicine. In practice, revenue-sharing and cost-sharing contracts are used to address such inefficiencies by better balancing and aligning the financial interests of drug and diagnostic manufacturers. We show that simple revenue-sharing and cost-sharing contracts can often, but not always, solve problems related to postponed or reduced investment, and we characterize settings where the pharmaceutical firm prefers revenue sharing over cost sharing. To account for different existing market structures, we compare the pharmaceutical firm’s contract preferences under regulated and free pharmaceutical pricing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect